In the study by Todorova et al. [63], women with ER+/PR+/Her2- or TNBC, stage I to III BC were enrolled, and all patients were histologically confirmed to have early stage invasive ductal carcinoma (IDC). This evidence concerns the gene ERBB2 and breast cancer.